Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XWELLSTU:V9G0 27 Net Margin % is -31.34% as of Jun. 2026. GuruFocus rates STU:V9G0 with a GF Score™ of 27/100 and a GF Value™ of €2.45. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, XWELL ranks worse than 78.33% on this metric.
Net margin is calculated as Net Income divided by its Revenue. XWELL's Net Income for the
three
months ended in Jun. 2026 was €-1.94 Mil. XWELL's Revenue for the
three
months ended in Jun. 2026 was €6.20 Mil. Therefore, XWELL's net margin for the quarter that ended in Jun. 2026 was -31.34%.
The historical rank and industry rank for XWELL's Net Margin % or its related term are showing as below:
STU:V9G0'
s Net Margin % Range Over the Past 10 Years
Min: -1079.17 Med: -58.89 Max: 4.54
Current: -82.9
STU:V9G0's Net Margin % is ranked worse than 78.33% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.74
vs STU:V9G0: -82.90
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
XWELL Net Margin % Related Terms
XWELL Net Margin % Historical Data
* Premium members only.
The historical data trend for XWELL's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:V9G0 vs MBAI, NDRA, BIAF: Net Margin % Comparison
For the Diagnostics & Research subindustry, XWELL's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XWELL Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's Net Margin % distribution charts can be found below:
* The bar in red indicates where XWELL's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XWELL (STU:V9G0) has a Net Margin % of -31.34% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on XWELL and its competitors. According to the industry distribution chart, XWELL ranks #159 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 78.3%.
Is XWELL's Net Margin % too high?
XWELL's current Net Margin % is -31.34%. Based on the distribution chart, XWELL ranks #159 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, XWELL has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does XWELL's Net Margin % compare to MBAI and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, XWELL ranks #159 out of 203 companies for Net Margin %. This places XWELL in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on XWELL and its competitors. XWELL's current Net Margin % is -31.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XWELL stock overvalued right now?
XWELL (STU:V9G0) has a current Net Margin % of -31.34%. The stock's GF Value™ is €2.45, compared to a current price of €2.96 — trading 20.8% above its estimated fair value. The current Net Margin % is -31.34%. XWELL's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For XWELL (STU:V9G0), the current Net Margin % is -31.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XWELL (STU:V9G0) Overvalued in 2026?
Based on GuruFocus' analysis, XWELL stock appears to be overvalued.
The current stock price of €2.96 is trading 20.8% above its estimated GF Value™ of €2.45.
Key valuation signals for STU:V9G0:
Net Margin %: -31.34%
GF Value™: €2.45 vs. price of €2.96 (20.8% above fair value)
No single metric tells the full story. See the STU:V9G0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.
27GF Score
Get the complete analysis for STU:V9G0
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:V9G0 has been successfully added to your 
